Latest & greatest articles for hydrochlorothiazide

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydrochlorothiazide or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hydrochlorothiazide and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hydrochlorothiazide

1. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use

Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use - GOV.UK GOV.UK uses cookies to make the site simpler. Search Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need (...) of hydrochlorothiazide (see of data below) inform patients taking hydrochlorothiazide-containing products of the risk of non-melanoma skin cancer, particularly in long-term use, and advise them to regularly check for and report any new or changed skin lesions or moles reconsider the use of hydrochlorothiazide in patients who have had previous skin cancer examine all suspicious moles or skin lesions (potentially including histological examination of biopsies) advise patients to limit their exposure to sunlight and UV

MHRA Drug Safety Update2018

2. Hydrochlorothiazide

Hydrochlorothiazide Top results for hydrochlorothiazide - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search (...) box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydrochlorothiazide The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic

Trip Latest and Greatest2018

3. RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), renin inhibitor, alone or in combination with a diuretic

RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), renin inhibitor, alone or in combination with a diuretic Haute Autorité de Santé - RASILEZ (aliskiren), RASILEZ HCT (aliskiren/hydrochlorothiazide), inhibiteur de la rénine, en association ou non à un diurétique Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments RASILEZ (aliskiren), RASILEZ (...) HCT (aliskiren/hydrochlorothiazide), inhibiteur de la rénine, en association ou non à un diurétique Substance active (DCI) RASILEZ : aliskiren RASILEZ HCT : aliskiren/hydrochlorothiazide CARDIOLOGIE - Mise au point Nature de la demande Réévaluation SMR Avis de la CT du 14 décembre 2016 Intérêt clinique insuffisant dans le traitement de l’hypertension artérielle pour justifier le maintien du remboursement RASILEZ a l’AMM dans le traitement de l’hypertension artérielle essentielle chez les adultes

Haute Autorite de sante2017

4. Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Randomised controlled trial: In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) hydrochlorothiazide lowers cardiovascular disease event rates Article Text Therapeutics/Prevention Randomised controlled trial In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates Michael LeFevre Statistics from Altmetric.com Commentary on: Lonn EM , Bosch J , López-Jaramillo P , et al . Blood-pressure lowering in intermediate-risk persons without cardiovascular disease . . Yusuf S, Bosch

Evidence-Based Medicine (Requires free registration)2016

5. Rasilez HCT (Aliskiren / hydrochlorothiazide) - essential hypertension

Rasilez HCT (Aliskiren / hydrochlorothiazide) - essential hypertension HAS - Medical, Economic and Public Health Assessment Division 1/15 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 4 December 2013 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 34009 392 151 6 7) RASILEZ HCT 150 mg/25 mg, film-coated tablets B/30 (CIP code: 34009 392 152 2 8) RASILEZ HCT 300 mg/12.5 mg, film-coated tablets B/30 (CIP code: 34009 392 153 9 6) RASILEZ HCT (...) 300 mg/25 mg, film-coated tablets B/30 (CIP code: 34009 392 154 5 7) Applicant: NOVARTIS PHARMA S.A.S. INN Aliskiren / hydrochlorothiazide ATC code (2008) C09XA52 (aliskiren and hydrochlorothiazide) Reason for the review Re-assessment of the actual benefit and the improvement in actual benefit, on the initiative of the Transparency Committee (in pursuance of Article R-163-21 of the Social Security Code). Renewal of inclusion Lists concerned National Health Insurance (French Social Security Code L

Haute Autorite de sante2014

6. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension?

How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? View/ Open Date 2014-04 (...) Format Metadata Abstract Q. How do hydrochlorothiazide and chlorthalidone compare for treating hypertension? A. Both medications reduce theincidence of cardiovascular events in patients with hypertension, but chlorthalidone may confer additional cardiovascular risk reduction (strength of recommendation [SOR]: B, conflicting network meta-analysis and cohort studies). (No head-to-head studies of hydrochlorothiazide [HCTZ] and chlorthalidone have been done.) Serious hypokalemia and hyponatremia can

Clinical Inquiries2014

7. Tolucombi - telmisartan / hydrochlorothiazide

Tolucombi - telmisartan / hydrochlorothiazide 26 February 2013 EMA/84367/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Tolucombi International non-proprietary name: telmisartan/hydrochlorothiazide Procedure No. EMEA/H/C/002549 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (0)20 7418 8400 (...) for the following indication: Treatment of essential hypertension. Tolucombi fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone. Tolucombi fixed dose combination (80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone. Tolucombi fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated

European Medicines Agency - EPARs2013

8. Actelsar HCT (telmisartan / hydrochlorothiazide)

Actelsar HCT (telmisartan / hydrochlorothiazide) 17 January 2013 EMA/163479/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Actelsar HCT International non-proprietary name: TELMISARTAN / HYDROCHLOROTHIAZIDE Procedure No. EMEA/H/C/002676/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom An agency of the European Union Telephone +44 (...) (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Product information Marketing authorisation application Name of the medicinal product: Actelsar HCT Applicant: Actavis Group hf Reykjavikurvegur 76-78 220 Hafnarfjordur ICELAND Active substance: telmisartan / hydrochlorothiazide International Nonproprietary Name/Common Name: telmisartan

European Medicines Agency - EPARs2013

9. Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT) - In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide (Sevikar HCT) - In adult patients whose blood pressure is not adequately controlled on the combination of olmesartan medoxomil and amlodipine taken as dual-component formulation.

Scottish Medicines Consortium2012

10. A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension

A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension 22805271 2012 07 18 2012 07 18 1742-1241 66 8 2012 Aug International journal of clinical practice Int. J. Clin. Pract. A 48-week study of amlodipine plus amiloride / hydrochlorothiazide vs. amlodipine plus telmisartan in the treatment of hypertension. 792-799 10.1111/j.1742-1241.2012.02943.x Background: Chinese Hypertension Intervention Efficacy (CHIEF) study (...) is a large-scale randomised clinical trial across China, which compares the efficacy of two combination regimens in reducing cardiovascular events associated with hypertension. Methods: We reported the 48-week efficacy and tolerability of the two antihypertensive regimens in participants from Shandong Province, China. Eligible patients aged 50-79 years were randomised to receive amlodipine plus amiloride/hydrochlorothiazide (Group A) or amlodipine plus telmisartan (Group B). The doses of both regimens

EvidenceUpdates2012

11. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials

Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S CRD summary (...) The authors concluded that hydrochlorothiazide (12.5mg to 25mg daily dose) lowered blood pressure significantly less well than other drug classes used to treat hypertension (measured by 24-hour ambulatory blood pressure monitoring). The reliability of the authors' conclusion is uncertain given potential error and bias in the review process and reliance on only a few high-quality trials. Authors' objectives To evaluate the antihypertensive efficacy of hydrochlorothiazide as assessed by ambulatory blood

DARE.2012

12. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses Roush GC, Holford TR, Guddati AK CRD summary This review and network meta-analysis concluded that chlortalidone (...) was better than hydrochlorothiazide for preventing cardiovascular events, in patients with hypertension. There were concerns about the limited search, poor reporting, and indirect analysis, but the results and conclusions are likely to be reliable. Authors' objectives To compare chlortalidone and hydrochlorothiazide for reducing the number of cardiovascular events, in patients with hypertension. Searching PubMed was searched, and Ovid was used to search for English-language publications, to July 2011

DARE.2012

13. Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece

Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece Economic evaluation of irbesartan in combination with hydrochlorothiazide in the treatment of hypertension in Greece Maniadakis N, Ekman M, Fragoulakis V, Papagiannopoulou V, Yfantopoulos J Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of irbesartan compared with losartan or valsartan, given in combination with hydrochlorothiazide, for hypertensive patients aged 40 to 80 years, from the payer perspective. The authors concluded that irbesartan

NHS Economic Evaluation Database.2011

14. Olmesartan medoxomil hydrochlorothiazide (Sevikar HCT) - as substitution therapy in adult patients whose blood pressure is adequately controlled

Olmesartan medoxomil hydrochlorothiazide (Sevikar HCT) - as substitution therapy in adult patients whose blood pressure is adequately controlled

Scottish Medicines Consortium2011

15. Ifirmacombi - irbesartan / hydrochlorothiazide

Ifirmacombi - irbesartan / hydrochlorothiazide 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8545 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. 16 December 2010 EMA/99460/2011 Committee for Medicinal Products for Human Use (CHMP) CHMP assessment report Ifirmacombi International (...) nonproprietary name: Irbesartan / Hydrochlorothiazide Procedure No. EMEA/H/C/002302 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. Table of contents 1. Background information on the procedure 3 1.1. Submission of the dossier 3 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 5 2.1. Introduction 5 2.2. Quality aspects 6 2.2.1. Introduction 6 2.2.2. Active Substance Irbesartan Hydrochloride 6 2.2.3. Active Substance

European Medicines Agency - EPARs2011

16. Rasitrio - aliskiren / amlodipine / hydrochlorothiazide

Rasitrio - aliskiren / amlodipine / hydrochlorothiazide 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union Assessment report for Rasitrio International non-proprietary name: aliskiren / amlodipine / hydrochlorothiazide Procedure No. EMEA/H/C/002017 Assessment Report as adopted by the CHMP with all information of a commercially (...) cardiovascular CV% coefficient of variation CYP Cytochrome P450 dependent enzyme, catalyzing oxidative drug metabolism DBP diastolic blood pressure DDI drug-drug interaction DRI direct renin inhibitor DSC Differential Scanning Calorimetry ECG electrocardiogram eGFR estimated glomerular filtration rate FAS full analysis set FMI final market image GC Gas Chromatography GCP Good Clinical Practice GLP Good Laboratory Practice GMP Good Manufacturing Practice HCTZ Hydrochlorothiazide HPLC High Performance Liquid

European Medicines Agency - EPARs2011

17. Sprimeo HCT - aliskiren / hydrochlorothiazide

Sprimeo HCT - aliskiren / hydrochlorothiazide 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. ASSESSMENT REPORT FOR Sprimeo HCT International Nonproprietary Name: aliskiren / hydrochlorothiazide Procedure No. EMEA/H/C/002421 Assessment (...) : “Treatment of essential hypertension in adults. Sprimeo HCT is indicated in patients whose blood pressure is not adequately controlled on aliskiren or hydrochlorothiazide used alone. Sprimeo HCT is indicated as substitution therapy in patients adequately controlled with aliskiren and hydrochlorothiazide, given concurrently, at the same dose level as in the combination.” Information on Paediatric requirements Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P

European Medicines Agency - EPARs2011

18. Riprazo HCT - aliskiren / hydrochlorothiazide

Riprazo HCT - aliskiren / hydrochlorothiazide 7 Westferry Circus ? Canary Wharf ? London E14 4HB ? United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail info@ema.europa.eu Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged. 20 January 2011 EMA/745107/2011 Committee for Medicinal Products for Human Use (CHMP) Assessment report Riprazo HCT aliskiren hemifumarate (...) / hydrochlorothiazide Procedure No.: EMEA/H/C/002420/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Medicinal product no longer authorised CHMP assessment report EMA/CHMP/30102/2011 Page 2/6 Table of contents 1. Background information on the procedure 3 1.1. Submission of the dossier 3 Information on Paediatric requirements 3 Scientific Advice 3 Licensing status 3 1.2. Steps taken for the assessment of the product 4 2. Scientific discussion 4

European Medicines Agency - EPARs2011

19. Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide)

Tribenzor (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Drug Approval Package: TRIBENZOR (olmesartan medoxomil and amlodipine) NDA #200175 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - TRIBENZOR (olmesartan medoxomil / amlodipine / hydrochlorothiazide) Tablets Company: Daiichi Sankyo, Inc. Application No.: 200175 Approval Date: 07/23/2010 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634

FDA - Drug Approval Package2010

20. Amturnide (amlodipine/aliskiren/hydrochlorothiazide)

Amturnide (amlodipine/aliskiren/hydrochlorothiazide) Drug Approval Package: Amturnide(amlodipine/aliskiren/hydrochlorothiazide) NDA #200045 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Amturnide (amlodipine/aliskiren/hydrochlorothiazide) 150/5/12.5 mg, 300/5/12.5 mg, 300/5/25 mg, 300/10/12.5 mg and 300/10/25 mg Tablets Company: Novartis Pharmaceuticals Application No.: 200045 Approval Date: 12/21/2010 Persons with disabilities having problems

FDA - Drug Approval Package2010